I4V-MC-JAHX: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506131-15-00

Acronym

I4V-MC-JAHX

Enrollment

Registered

2024-04-04

Start date

2019-09-10

Completion date

Unknown

Last updated

2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Idiopathic Arthritis

Brief summary

Number of participants with one or more SAEs, Number of participants with permanent investigational product discontinuations

Interventions

DRUGBaricitinib

DRUGBARICITINIB

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Number of participants with one or more SAEs, Number of participants with permanent investigational product discontinuations	—

Countries

Austria, Belgium, Czechia, Denmark, France, Germany, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026